These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22648764)

  • 1. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease.
    Han SD; Gruhl J; Beckett L; Dodge HH; Stricker NH; Farias S; Mungas D;
    Brain Imaging Behav; 2012 Dec; 6(4):610-20. PubMed ID: 22648764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
    Dowling NM; Johnson SC; Gleason CE; Jagust WJ;
    Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer's disease: a longitudinal study.
    Nabizadeh F; Seyedmirzaei H; Karami S
    Sci Rep; 2024 Jul; 14(1):15318. PubMed ID: 38961148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade.
    Stricker NH; Dodge HH; Dowling NM; Han SD; Erosheva EA; Jagust WJ;
    Brain Imaging Behav; 2012 Dec; 6(4):599-609. PubMed ID: 22614327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
    Shaw LM; Vanderstichele H; Knapik-Czajka M; Figurski M; Coart E; Blennow K; Soares H; Simon AJ; Lewczuk P; Dean RA; Siemers E; Potter W; Lee VM; Trojanowski JQ;
    Acta Neuropathol; 2011 May; 121(5):597-609. PubMed ID: 21311900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
    Savage MJ; Holder DJ; Wu G; Kaplow J; Siuciak JA; Potter WZ;
    J Alzheimers Dis; 2015; 46(2):431-40. PubMed ID: 25790831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional relationships between CSF VEGF levels and Alzheimer's disease brain biomarkers and cognition.
    Tubi MA; Kothapalli D; Hapenney M; Feingold FW; Mack WJ; King KS; Thompson PM; Braskie MN;
    Neurobiol Aging; 2021 Sep; 105():241-251. PubMed ID: 34126466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for ordering of Alzheimer disease biomarkers.
    Jack CR; Vemuri P; Wiste HJ; Weigand SD; Aisen PS; Trojanowski JQ; Shaw LM; Bernstein MA; Petersen RC; Weiner MW; Knopman DS;
    Arch Neurol; 2011 Dec; 68(12):1526-35. PubMed ID: 21825215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
    Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
    Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
    Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
    JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion.
    Westman E; Muehlboeck JS; Simmons A
    Neuroimage; 2012 Aug; 62(1):229-38. PubMed ID: 22580170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer's and Lewy Body Diseases.
    Schaeffer MJ; Callahan BL;
    J Alzheimers Dis; 2019; 70(3):877-887. PubMed ID: 31282412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
    Shaw LM; Vanderstichele H; Knapik-Czajka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter W; Lee VM; Trojanowski JQ;
    Ann Neurol; 2009 Apr; 65(4):403-13. PubMed ID: 19296504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation.
    Skouras S; Torner J; Andersson P; Koush Y; Falcon C; Minguillon C; Fauria K; Alpiste F; Blenow K; Zetterberg H; Gispert JD; Molinuevo JL;
    Brain; 2020 Mar; 143(3):976-992. PubMed ID: 32091109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.